According to our latest research study, “Global Protein Therapeutics Market Analysis”, the growth experienced in the segment under blood clotting factors will boost the overall growth of global protein therapeutics market in the coming years. The growth in the blood clotting factor market is based on the rising population with increase in the number of hemophilia patients, new innovations in drug delivery, better therapies with less side effects, and increasing provisions of health insurance. Besides, the increasing regulatory support around the world towards the segment along with increasing generic competition will help the blood clotting market to grow at a CAGR of around 17% during 2012-2014.
Besides, our report also provides a thorough research and prudent analysis of global protein therapeutics market. The systematic and thorough research studies the global protein therapeutics market that will provide an insight into its various segments including Monoclonal Antibodies, Erythropoietins, Insulin, Interferon, Human Growth Hormone, Granulocyte Colony Stimulating Factor, and Follicle Stimulating Hormone. The comprehensive analysis of the market states blood clotting factors to be one of the highest shareholders at present.
We have identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that increase in the health insurance industry will drive renewed interest of the investors in the therapeutics market at the global level. Moreover, higher incidence of lifestyle and chronic diseases, such as cancer, arthritis, etc. will pave the way for the growth of the market in coming years. In terms of technology, the focus of the research community is shifting towards synthetic biology and the development of drug-like therapies and multi-functional therapies.
Comments On Segment of Blood Clotting Factor Set to Drive Global Protein Therapeutics Market0